Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator ...

In a groundbreaking review published in Current Molecular Pharmacology, a team led by Dr. Jhi Biau Foo from Taylor’s University unveils the pivotal role of mutant p53 (mutp53) in driving cancer ...

(“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced that results from the ...

The tumor suppressor protein p53 plays a critical role in preventing cancer by regulating cell cycle, apoptosis, and genomic stability. However, mutations in the P53 gene are found in over 50% of ...

In this review, the authors present recent findings that uncover a previously unappreciated nuclear signaling hub: the PIPn-p53 signalosome. This complex not only modulates AKT activation within the ...

Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life. The treatment landscape for chronic lymphocytic leukemia (CLL) has undergone a seismic shift, moving from the ...

Phase II study to evaluate surufatinib in patients with osteosarcoma and soft tissue sarcoma that has failed standard chemotherapy: Updated analysis. This is an ASCO Meeting Abstract from the 2024 ...

Scientists have recently shed some light on exactly why elephants, one of the biggest animals on the planet, paradoxically experience unusually low rates of cancer. The research found these remarkable ...

I’M MINDY BASARA IN TODAY’S MEDICAL ALERT. RADIATION THERAPY IS A COMMON TREATMENT FOR CANCER. ABOUT HALF OF ALL CANCER PATIENTS WILL RECEIVE IT. ONE OF THE DOWNSIDES OF TRADITIONAL RADIATION IS THAT ...